Morgan Stanley covers eight biotech companies in one go! PTC Therapeutics (PTCT.US) and Belite Bio (BLTE.US) are favored, highlighting several potential blockbuster drugs.

According to Jin Zhi Finance APP, Morgan Stanley recently released a research report initiating coverage of eight biotechnology companies involved in rare diseases, ophthalmology, pulmonary diseases, and neuropsychiatric disorders. The firm is particularly optimistic about the growth potential of PTC Therapeutics (PTCT.US) driven by Sephience, as well as the opportunity for Belite Bio (BLTE.US) to become the first approved and marketed therapy for Stargardt disease. Meanwhile, the firm is also watching Trevi Therapeutics (TRVI.US) for its market opportunities in the chronic cough sector and sees potential for COMPASS Pathways (CMPS.US) to enter the commercialization stage by 2027.